Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Endometrial cancer is one of the gynecologic malignancies most strongly associated with obesity, yet the biological basis of this association extends beyond excess adiposity as a risk factor. Obesity reshapes the endometrial ecosystem through peripheral estrogen excess, progesterone imbalance, insulin resistance, adipokine dysregulation, chronic inflammation, and activation of anabolic signaling pathways. These mechanisms converge on metabolic programs that support proliferation, invasion, immune remodeling, and treatment resistance. Polyamine metabolism is emerging as a potentially relevant but still incompletely validated layer of this biology. Ornithine decarboxylase 1, the rate-limiting enzyme in polyamine biosynthesis, is overexpressed in aggressive endometrial cancers and has been associated with recurrence and poor survival. Recent evidence further suggests that metabolic syndrome-associated oleic acid may stabilize homeobox B9, protect ornithine decarboxylase 1 from degradation, increase polyamine accumulation, and promote tumor progression. This Mini Review critically examines the obesity–estrogen–polyamine axis as an integrative framework linking endocrine dysfunction, inflammatory remodeling, lipid signaling, and proliferative metabolic rewiring in endometrial cancer. It also discusses biomarker opportunities, therapeutic vulnerabilities, and the translational gaps that must be addressed before this axis can inform precision oncology.